FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569328097> ?p ?o ?g. }

• W1569328097 abstract "Background Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness. Objectives To review the efficacy of oxcarbazepine, relative to placebo and other agents, in the prevention of affective episodes of bipolar affective disorder. The efficacy of oxcarbazepine was considered in terms of episode recurrence, general and social functioning. Adverse effects, overall acceptability to participants and mortality were also considered. Search methods CCDANCTR‐Studies and CCDANCTR‐References were searched on 7/11/2007. Medline, CENTRAL, EMBASE and PsycINFO were searched in March 2007. Specialist journals and conference proceedings were handsearched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Authors, experts in the field and pharmaceutical companies were contacted requesting information on published or unpublished trials. Selection criteria Randomised controlled trials comparing oxcarbazepine with placebo or alternative agents, where the stated intent of intervention was the maintenance treatment of bipolar affective disorder were sought. Participants with bipolar disorder, male and female, of all ages, were included. Data collection and analysis Data were extracted from the original reports individually by two review authors. The methodological quality of included studies was assessed individually by two review authors. The main outcomes were the efficacy of oxcarbazepine maintenance treatment in preventing or attenuating further episodes of bipolar affective disorder (including its efficacy in rapid cycling disorder), the acceptability of oxcarbazepine treatment to participants, the prevalence of side‐effects, and mortality, if any, on oxcarbazepine treatment. Where appropriate, data concerning outcome measures and adverse effects were to be extracted from the studies and analysed using Review Manager software. Main results Two randomised controlled trials were found that met the methodological criteria for inclusion in the review. However, they did not report data with sufficient clarity to allow their confident extraction for inclusion in the meta‐analysis. Findings from the two studies were presented descriptively. Authors' conclusions There is an insufficient methodologically rigorous evidence base to provide guidance on the use of oxcarbazepine in the maintenance treatment of bipolar disorder. Given the need for more efficacious therapeutic agents, there is a need for good quality randomised controlled trials examining the therapeutic potential of this and related agents in bipolar disorder." @default.
• W1569328097 created "2016-06-24" @default.
• W1569328097 creator A5055176833 @default.
• W1569328097 creator A5069770468 @default.
• W1569328097 creator A5074939684 @default.
• W1569328097 creator A5077069113 @default.
• W1569328097 creator A5087798145 @default.
• W1569328097 date "2008-01-23" @default.
• W1569328097 modified "2023-09-26" @default.
• W1569328097 title "Oxcarbazepine in the maintenance treatment of bipolar disorder" @default.
• W1569328097 cites W1521911962 @default.
• W1569328097 cites W1591259115 @default.
• W1569328097 cites W1968023701 @default.
• W1569328097 cites W1975577573 @default.
• W1569328097 cites W1986215651 @default.
• W1569328097 cites W1992409140 @default.
• W1569328097 cites W2035144713 @default.
• W1569328097 cites W2040674531 @default.
• W1569328097 cites W2053154970 @default.
• W1569328097 cites W2053818301 @default.
• W1569328097 cites W2065151935 @default.
• W1569328097 cites W2069959657 @default.
• W1569328097 cites W2086460119 @default.
• W1569328097 cites W2089287942 @default.
• W1569328097 cites W2094857518 @default.
• W1569328097 cites W2096240671 @default.
• W1569328097 cites W2107198625 @default.
• W1569328097 cites W2107328434 @default.
• W1569328097 cites W2120608834 @default.
• W1569328097 cites W2127656341 @default.
• W1569328097 cites W2168953165 @default.
• W1569328097 cites W4214559180 @default.
• W1569328097 doi "https://doi.org/10.1002/14651858.cd005171.pub2" @default.
• W1569328097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6956443" @default.
• W1569328097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18254071" @default.
• W1569328097 hasPublicationYear "2008" @default.
• W1569328097 type Work @default.
• W1569328097 sameAs 1569328097 @default.
• W1569328097 citedByCount "21" @default.
• W1569328097 countsByYear W15693280972012 @default.
• W1569328097 countsByYear W15693280972013 @default.
• W1569328097 countsByYear W15693280972014 @default.
• W1569328097 countsByYear W15693280972016 @default.
• W1569328097 countsByYear W15693280972018 @default.
• W1569328097 countsByYear W15693280972021 @default.
• W1569328097 crossrefType "journal-article" @default.
• W1569328097 hasAuthorship W1569328097A5055176833 @default.
• W1569328097 hasAuthorship W1569328097A5069770468 @default.
• W1569328097 hasAuthorship W1569328097A5074939684 @default.
• W1569328097 hasAuthorship W1569328097A5077069113 @default.
• W1569328097 hasAuthorship W1569328097A5087798145 @default.
• W1569328097 hasBestOaLocation W15693280972 @default.
• W1569328097 hasConcept C118552586 @default.
• W1569328097 hasConcept C126322002 @default.
• W1569328097 hasConcept C142724271 @default.
• W1569328097 hasConcept C15744967 @default.
• W1569328097 hasConcept C168563851 @default.
• W1569328097 hasConcept C17744445 @default.
• W1569328097 hasConcept C197934379 @default.
• W1569328097 hasConcept C199539241 @default.
• W1569328097 hasConcept C204787440 @default.
• W1569328097 hasConcept C27081682 @default.
• W1569328097 hasConcept C2776174506 @default.
• W1569328097 hasConcept C2776809841 @default.
• W1569328097 hasConcept C2778186239 @default.
• W1569328097 hasConcept C2779253243 @default.
• W1569328097 hasConcept C2779473830 @default.
• W1569328097 hasConcept C2779549880 @default.
• W1569328097 hasConcept C2780733359 @default.
• W1569328097 hasConcept C2781176495 @default.
• W1569328097 hasConcept C2781246090 @default.
• W1569328097 hasConcept C70410870 @default.
• W1569328097 hasConcept C71924100 @default.
• W1569328097 hasConceptScore W1569328097C118552586 @default.
• W1569328097 hasConceptScore W1569328097C126322002 @default.
• W1569328097 hasConceptScore W1569328097C142724271 @default.
• W1569328097 hasConceptScore W1569328097C15744967 @default.
• W1569328097 hasConceptScore W1569328097C168563851 @default.
• W1569328097 hasConceptScore W1569328097C17744445 @default.
• W1569328097 hasConceptScore W1569328097C197934379 @default.
• W1569328097 hasConceptScore W1569328097C199539241 @default.
• W1569328097 hasConceptScore W1569328097C204787440 @default.
• W1569328097 hasConceptScore W1569328097C27081682 @default.
• W1569328097 hasConceptScore W1569328097C2776174506 @default.
• W1569328097 hasConceptScore W1569328097C2776809841 @default.
• W1569328097 hasConceptScore W1569328097C2778186239 @default.
• W1569328097 hasConceptScore W1569328097C2779253243 @default.
• W1569328097 hasConceptScore W1569328097C2779473830 @default.
• W1569328097 hasConceptScore W1569328097C2779549880 @default.
• W1569328097 hasConceptScore W1569328097C2780733359 @default.
• W1569328097 hasConceptScore W1569328097C2781176495 @default.
• W1569328097 hasConceptScore W1569328097C2781246090 @default.
• W1569328097 hasConceptScore W1569328097C70410870 @default.
• W1569328097 hasConceptScore W1569328097C71924100 @default.
• W1569328097 hasLocation W15693280971 @default.
• W1569328097 hasLocation W15693280972 @default.
• W1569328097 hasLocation W15693280973 @default.
• W1569328097 hasLocation W15693280974 @default.
• W1569328097 hasOpenAccess W1569328097 @default.
• W1569328097 hasPrimaryLocation W15693280971 @default.

• next